SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Under the Securities Exchange Act of 1934
Final Amendment (Amendment No. 2)*
Prothena Corporation Public Limited Company
(Name of Issuer)
Ordinary Shares, par value $0.01 per share
(Title of Class of Securities)
June 30, 2019
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
|*||Theremainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.|
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|CUSIP NO. G72800108||SCHEDULE 13G||Page 2 of 6|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)
Woodford Patient Capital Trust Plc
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
SEC USE ONLY
CITIZENSHIP OR PLACE OF ORGANIZATION
OWNED BY EACH
SOLE VOTING POWER
SHARED VOTING POWER
SOLE DISPOSITIVE POWER
SHARED DISPOSITIVE POWER
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% (See Item 4)
TYPE OF REPORTING PERSON
|CUSIP NO. G72800108||SCHEDULE 13G||Page 3 of 6|
This Amendment No. 2 amends and restates in its entirety the Schedule 13G filed by Woodford Patient Capital Trust Plc on February 13, 2018, as amended by Amendment No. 1 thereto on February 14, 2019 (as amended and restated, this “Schedule 13G”). This Amendment No. 2 is the final amendment to the Schedule 13G and is an exit filing.
|Item 1(a).||Name of Issuer:|
|Prothena Corporation Public Limited Company (the “Issuer”).|
|Item 1(b).||Address of Issuer’s Principal Executive Offices:|
|Upper George’s Street|
|Co. Dublin, A96 T927, Ireland|
|(b) and (c).||Name of Persons Filing, Address of Principal Business Office and Citizenship:|
This Schedule 13G is being filed on behalf of Woodford Patient Capital Trust Plc (the “Reporting Person”).
The principal business office of the Reporting Person is 9400 Garsington Road, Oxford OX4 2HN, United Kingdom. For the place of organization, see Item 4 of the cover page.
|Item 2(d).||Title of Class of Securities:|
Ordinary Shares, par value $0.01 per share (the ” Ordinary Shares”).
|Item 2(e).||CUSIP Number:|
|Item 3.||If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:|
|(a)||☐||Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).|
|(b)||☐||Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).|
|(c)||☐||Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐ 78c).|
|(d)||☐||Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).|
|(e)||☐||An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);|
|(f)||☐||An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);|
|(g)||☐||A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);|
|CUSIP NO. G72800108||SCHEDULE 13G||Page 4 of 6|
|(h)||☐||A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);|
|(i)||☐||A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);|
|(j)||☒||A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).|
Group, in accordance with §240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: The Reporting Person is eligible to file pursuant to §240.13d-1(b)(1)(ii)(J) and is an investment company authorized and regulated by the Financial Conduct Authority of the United Kingdom which is comparable to the regulatory scheme applicable to the investment companies covered by Item 3(d) above.
|(a)||Amount beneficially owned:|
0 Ordinary Shares.
|(b)||Percent of class:|
Based on 39,864,561 Ordinary Shares of the Issuer outstanding as of April 30, 2019, as reported in the Issuer’s Current Report on Form 10-Q, filed with the SEC on May 7, 2019, the Reporting Person beneficially owns 0% of the issued and outstanding Ordinary Shares of the Issuer.
|(c)||Number of shares to which such person has:|
|(i)||Sole power to vote or direct the vote: 0|
|(ii)||Shared power to vote or direct the vote: 0 Ordinary Shares|
|(iii)||Sole power to dispose or to direct the disposition of: 0|
|(iv)||Shared power to dispose of or direct the disposition of: 0 Ordinary Shares|
|CUSIP NO. G72800108||SCHEDULE 13G||Page 5 of 6|
|Item 5.||Ownership of Five Percent or Less of a Class.|
If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒.
|Item 6.||Ownership of More than Five Percent on Behalf of Another Person.|
|Item 7.||Identification and Classification of the Subsidiary Which Acquired the Security Being Reported By the Parent Holding Company.|
|Item 8.||Identification and Classification of Members of the Group.|
|Item 9.||Notice of Dissolution of a Group.|
By signing below I certify that, to the best of my knowledge and belief, (i) the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect and (ii) the foreign regulatory scheme applicable to investment companies authorized and regulated by the Financial Conduct Authority of the United Kingdom is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.
|CUSIP NO. G72800108||SCHEDULE 13G||Page 6 of 6|
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: July 9, 2019
|Woodford Patient Capital Trust PLC|
|by: Woodford Investment Management Ltd, its Manager|
|By:||/s/ Chris Martin|
|Title:||Head of Compliance and|